MedPath

Effects of melatonin on depression and cognition function in hemodialyzed patients, A randomized, double-blind, controlled trial

Phase 2
Recruiting
Conditions
Chronic kidney disease, Hemodialysis.
Chronic kidney disease, stage 5
Registration Number
IRCT20110226005914N3
Lead Sponsor
Oroumia University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
50
Inclusion Criteria

They should be hemodialized for at least 3 months and 3 times per week and 4 hours per visit.
They should be fluent in Farsi language .
They should have visual and auditory health to complete the questionnaire.

Exclusion Criteria

Have diabetes type 1 or 2.
Have psychotic disease
Take antidepressant medicationss.
Take anti-anxiety/sedative medications.

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Depression Score in the Beck Questionnaire.Cognitive impairment Score in the MMSE Questionnaire. Timepoint: Before starting the medication and two months after taking Melatonin tablets. Method of measurement: Beck Depression questionnare and MMSE Cognitive Impairment questionnaire.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath